BTK and B-cell chronic lymphocytic leukemia: This will likely also hold true in the current era of novel anti-CLL drug approvals targeting Bruton's tyrosine kinase (BTK), phosphatidylinositol-3-kinase delta (PI3Kδ) and B-cell lymphoma/leukemia 2 (BCL-2) [8].